URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


4th Neuroimmunology Drug Development Summit


Date
Apr 18, 2022 - 08:30 AM - Apr 20, 04:10 PM
Organizer
Hanson Wade
Venue
Wyndham Boston Beacon Hill
Location
5, Blossom St

Boston,
MA,
USA,
ZIP: 02114
Phone: +16174554188

Ticket Price: USD 2999.0 - USD 5195.0


Since 2019, venture capitalists have been predicting a "golden era of neuroscience products" and successes of "radical new breakthrough therapies" in the notoriously challenging space.

Now, three years on, 2022 is hosting the neuroscience renaissance and pharma is doubling down to understand the neuropathological and neuroprotective role of neuroinflammation as the most promising opportunity to bring more targeted, precise and transformative therapies to neurodegenerative and neuropsychiatric diseases.

The 4th Neuroimmunology Drug Development Summit is the timely, industry-definitive forum providing actionable insights to target neuroimmunological mechanisms and advance drug development addressing neuroinflammation.

Download the full event guide here to view the full speaking faculty including Alector, Biogen, Lundbeck, Eisai and Elixiron Therapeutics.

Bringing together department and pipeline Heads across biopharma drug development, join over 100 colleagues to discuss the role of astrocytes, oligodendrocytes and peripheral immune cells; biomarker combinations to diagnose, stratify and design more successful clinical trials; and progress and potential of iPSC-derived organoids for more robust and translatable drug discovery and development research.

Want more content? With four additional workshops hosting detailed discussion and even more focused scientific insights, attend our workshop day to further your understanding into emerging areas of research expansion for neurological pipelines, including: the relationship with traumatic brain injury (TBI) and neuroinflammation, the gut-brain axis, and targeting genetic risk factors in various neurodegenerative, neuropsychiatric and behavioural impairments.

URLs:
Tickets: https://go.evvnt.com/956949-2?pid=1052
Brochure: https://go.evvnt.com/956949-3?pid=1052

Prices:
Industry Pricing - Conference Only: USD 2999.0,
Industry Pricing - Conference + 1 Workshop: USD 3298.0,
Industry Pricing - Conference + 2 Workshops: USD 3597.0,
Industry Pricing - Conference + 3 Workshops: USD 3896.0,
Industry Pricing - Conference + 4 Workshops: USD 4196.0,
Vendor Pricing - Conference Only: USD 3599.0,
Vendor Pricing - Conference + 1 Workshop: USD 3998.0,
Vendor Pricing - Conference + 2 Workshops: USD 4397.0,
Vendor Pricing - Conference + 3 Workshops: USD 4796.0,
Vendor Pricing - Conference + 4 Workshops: USD 5195.0


Speaker Details


Alejandro Rangel, Applied Neurosciences Department Head, Mexican Council of Neuroscience, Andrea Crotti, Principal Scientist, Takeda Pharmaceutical, Andrew Koemeter-Cox, Associate Director, The Michael J Fox Foundation for Parkinson's Disease, Brenda Moore, Research Assistant Professor, University of Florida, Christopher Barnum, Head of Neuroscience, Inmune Bio, Dimitry Ofengeim, Head of Precision Neurology and Neuroinflammation, Sanofi Genzyme, Dong Seok Kim, Chief Executive Officer, Aevis Bio, Francisco Javier Quintana, Professor of Neurology; Associate Member Ann Romney Centre for Neurologic Diseases Brigham and Women's Hospital; Harvard Medicine School; The Broad Institute, Hung-Kai (Kevin) Chen, Chairman and Chief Executive, Officer Elixiron Immunotherapeutics, Jennifer Barnett, Chief Executive Officer, Monument Therapeutics, Jesse Cedarbaum, Acting Chief Medical Officer, ImmnuoBrain Checkpoint, Johan Luthman, Executive Vice President and Head of R and D, Lundbeck A/S, Johannes Grosse, Senior Director of Drug Discovery, Vir Biotechnology, Julie Huang, Senior Scientist, Biomarker Sciences, Alector, Kuti Baruch, Head of R and D, ImmunoBrain Checkpoint, LuLin Jiang, Staff Scientist, Sanford Burnham Prebys Medical Discovery Institute, Malu Tansey, Professor of Neuroscience and Neurology; Co-Director University of Florida College of Medicine; Centre for Translational Research in Neurodegenerative Disease, Marianthi Papakosta, Head of In Vitro Neuroinflammation Pharmacology, Cell Protection Unit and Neuroscience, Takeda Pharmaceuticals, Mark Treherne, Chairman, Talisman Therapeutics, Michael Mingueneau, Director of Research, Biogen, Mike Nagle, Senior Director, Head of Neurogenomics, Eisai, Nikhil Sharma, Founder and Chief Executive Officer, BioCortex, Olivia Corradin, Assistant Professor of Biology, MIT, Paul Ashton, Chief Executive Officer and President, Inflammasome Therapeutics, Richard Wyse, Director of R and D, The Cure Parkinson's Trust, Stan Chamberlain, Chief Scientific Officer, T3D Therapeutics, Stanley Appel, Co-Director, Houston Methodist Neurological Institute; Advisory Board Chair COYA Therapeutics, Thomas Nieland, Director and Head of Target Validation and Exploratory Biology, Verge Genomics, Yung-Chih (Inge) Cheng, Principal Scientist, Pfizer

Event Categories
Keywords: pharmaceutical




Comments








Events Calendar

SunMonTueWedThuFriSat
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Event Location

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99